
The propensity score–matched cohort study analyzed data from 17,642 acute coronary syndrome (ACS) patients undergoing invasive treatment to evaluate the safety and effectiveness of ticagrelor vs prasugrel. Over a 1-year follow-up, prasugrel was associated with a lower incidence of the composite endpoint (all-cause mortality, MI, or stroke: HR 1.24; 95% CI 1.12-1.37), with significant reductions in myocardial infarction (HR 1.20) and stroke (HR 1.33). No significant differences in stent thrombosis or major bleeding were observed. Findings underscore prasugrel's potential as a preferred agent in ACS, especially in ST-segment elevation MI cases.
Like
Save
Share